These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
38 related articles for article (PubMed ID: 2604775)
21. [Experimental study of the effects of potassium acetate inhalation]. Grin' NV; Pavlovich LV; Govorunova NN; Bessmertnyĭ AN; Besedina EI Gig Sanit; 1993 Mar; (3):8-9. PubMed ID: 8063147 [No Abstract] [Full Text] [Related]
22. [Calcium phosphate metabolism during therapy with 1,25-dihydroxycholecalciferol [1,25 DHCC (Ro 21/5535)] in patients with advanced kidney insufficiency]. Schulz W; Spiegel P; Gessler U; Delling G Verh Dtsch Ges Inn Med; 1978; (84):1297-301. PubMed ID: 741953 [No Abstract] [Full Text] [Related]
23. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
24. After several years of witchhunting, can calcium-based phosphate binding be released on probation? Ketteler M; Biggar P Nephrol Dial Transplant; 2008 Jan; 23(1):17-9. PubMed ID: 18039641 [No Abstract] [Full Text] [Related]
25. [Basal excretion and excretion after PTH phosphate and AMPc administration in non-advanced chronic renal failure ]. Sánchez Rodríguez LM; Rodríguez Commes JL; González Macías J; Sánchez Rodríguez A; Martín Rodríguez M Med Clin (Barc); 1982 Jun 16-30; 79(2):65-9. PubMed ID: 6289022 [No Abstract] [Full Text] [Related]
29. [Calcium and phosphate metabolism]. Kotzaurek R Wien Klin Wochenschr; 1971 Aug; 83(33):581-90. PubMed ID: 5110488 [No Abstract] [Full Text] [Related]
30. Efficacy of ferric citrate as a phosphate-binding agent in end-stage renal disease. Ghosh AK Nephrol Dial Transplant; 2002 Jul; 17(7):1354; author reply 1354. PubMed ID: 12105267 [No Abstract] [Full Text] [Related]
31. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523 [TBL] [Abstract][Full Text] [Related]
32. Effect of the time of administration of calcium acetate on phosphorus binding. Schiller LR; Santa Ana CA; Sheikh MS; Emmett M; Fordtran JS N Engl J Med; 1989 Apr; 320(17):1110-3. PubMed ID: 2710173 [TBL] [Abstract][Full Text] [Related]
33. Influence of keto acids on serum parathyroid hormone levels in patients with chronic renal failure. Fröhling PT; Kokot F; Schmicker R; Kaschube I; Lindenau K; Vetter K Clin Nephrol; 1983 Oct; 20(4):212-5. PubMed ID: 6641029 [TBL] [Abstract][Full Text] [Related]
34. Some fresh observations on calcium and phosphate metabolism in chronic renal failure. de Wardener HE Sci Basis Med Annu Rev; 1972; ():248-72. PubMed ID: 4564345 [No Abstract] [Full Text] [Related]
35. Time of administration of calcium acetate and phosphate binding. Diskin CJ; Thomas CE; Zellner CP N Engl J Med; 1989 Sep; 321(13):904-5. PubMed ID: 2604775 [No Abstract] [Full Text] [Related]